Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer

Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Holder, S L, Drabick, J, Zhu, J, Joshi, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Journal Clubs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622618/
https://www.ncbi.nlm.nih.gov/pubmed/25756508
http://dx.doi.org/10.1080/15384047.2014.1002687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622618/
https://www.ncbi.nlm.nih.gov/pubmed/25756508
http://dx.doi.org/10.1080/15384047.2014.1002687

Ejemplares similares